GoodRx Brings Employer Access to Zepbound Weight-Loss Drug Through New Benefit Model

The surge in demand for GLP-1 weight-loss medications is forcing employers to rethink how they cover high-cost therapies. Now GoodRx is introducing a new pathway designed to make those treatments more predictable and accessible.

The prescription savings platform announced employer-sponsored access to Zepbound, the obesity treatment developed by Eli Lilly and Company, through its GoodRx Employer Direct program. Under the model, self-insured employers can provide employees with the Zepbound KwikPen at a set price of $449 across all doses, with the option to further subsidize the medication at the pharmacy counter.

The initiative positions GoodRx as a bridge between pharmaceutical manufacturers, employers, and pharmacies—an increasingly valuable role as companies search for cost-effective ways to address employee demand for weight-management treatments.

A New Approach to GLP-1 Coverage

GLP-1 drugs have become some of the most talked-about—and expensive—therapies in modern healthcare. Medications in this class are widely prescribed for diabetes and obesity management, but their high price tags have made coverage decisions difficult for employers and health plans.

Through its collaboration with Lilly’s Employer Connect program, GoodRx is aiming to simplify the equation.

According to Laura Jensen, Chief Commercial Officer and President of Pharma Direct at GoodRx, the model combines manufacturer pricing and employer contributions within a single infrastructure.

“Employers are navigating rising demand for GLP-1 obesity treatments and need predictable, transparent affordability solutions,” Jensen said. “Our collaboration with Lilly demonstrates how GoodRx connects manufacturer pricing and employer contributions in a single infrastructure.”

The goal is to give employers a clearer and more manageable pricing structure while expanding access for employees seeking weight-management therapies.

How GoodRx Employer Direct Works

The new offering is built on the company’s Employer Direct platform, which allows companies to sponsor certain medications outside of traditional insurance formularies.

In practice, the system works as follows:

• Lilly sets a standardized price of $449 for Zepbound KwikPen under its Employer Connect program

• Employers decide how much of that price they want to subsidize

• The employer contribution is automatically applied at the pharmacy counter

• Employees pay the remaining amount, if any, when filling the prescription

Importantly, the program operates alongside existing health plans rather than replacing them.

Employers do not need to alter their core benefits or pharmacy benefit manager (PBM) arrangements. Instead, the solution acts as a supplemental access pathway designed specifically for high-demand medications.

Telehealth Access for Weight-Loss Treatment

The program also integrates with a telemedicine offering called GoodRx for Weight Loss, which can be branded for participating employers.

The direct-to-consumer telehealth platform allows employees to:

• Consult with licensed healthcare providers

• Complete eligibility and health assessments

• Discuss treatment options

• Receive prescriptions when clinically appropriate

If approved and consistent with FDA labeling guidelines, employees may receive a prescription for Zepbound KwikPen through the program.

This end-to-end model aims to streamline the treatment journey—from medical consultation to pharmacy pickup—within a single digital ecosystem.

Addressing Employer Concerns Around Cost

For employers, the biggest challenge surrounding GLP-1 drugs has been cost predictability.

Traditional insurance coverage can expose companies to significant pharmacy spending as more employees seek access to weight-management medications. In some cases, companies have restricted coverage entirely due to budget concerns.

Kevin Hern, Senior Vice President of Lilly Employer at Lilly USA, said employers frequently express a desire to support employee health but struggle with the financial implications of covering obesity treatments.

“Employers continue to tell us they want to better support their employees’ health but face real challenges in providing coverage for obesity management medicines,” Hern said.

The partnership with GoodRx aims to offer a more flexible framework that allows employers to control costs while still expanding access.

Building an Integrated Healthcare Access Platform

Beyond the specific Zepbound program, the announcement highlights GoodRx’s broader strategy to create an integrated healthcare access platform.

Through its Pharma Direct infrastructure, pharmaceutical manufacturers can offer discounted pricing directly within the GoodRx ecosystem. Employer Direct then layers employer contributions on top of that pricing in real time at the pharmacy counter.

The result is a unified system connecting manufacturers, employers, pharmacies, and patients.

For the healthcare and HR technology sectors, the model reflects a growing push toward alternative benefit designs that bypass traditional insurance structures for certain therapies.

The Future of Employer Health Benefits

The demand for GLP-1 medications shows little sign of slowing. Analysts estimate that the global market for obesity drugs could reach tens of billions of dollars over the next decade.

That surge is forcing employers to rethink how they design health benefits.

Some organizations are limiting access to control costs, while others are exploring new models—like employer-sponsored discount programs, telehealth pathways, and direct manufacturer partnerships.

GoodRx’s latest move suggests that hybrid benefit structures could become more common as companies balance employee health needs with financial sustainability.

If the approach proves effective, similar programs could emerge for other high-cost therapies, potentially reshaping how employer-sponsored healthcare benefits are delivered in the future.

Join thousands of HR leaders who rely on HRTechEdge for the latest in workforce technology, AI-driven HR solutions, and strategic insights